Literature DB >> 35470783

An innovative systematic approach introduced the involved lncRNA-miR-mRNA network in cell cycle and proliferation after conventional treatments in breast cancer patients.

Maryam Mohsenikia1, Solmaz Khalighfard2, Ali Mohammad Alizadeh3,4, Vahid Khori5, Maziar Ghandian Zanjan5, Mohammadreza Zare5, Ramesh Omranipour3, Elham Patrad4, Hengamesadat Razavi4, Ziba Veisi Malekshahi6, Zahra Bagheri-Hosseinabadi7.   

Abstract

The present study aimed to explore the involved lncRNA-miRNA-mRNA network in the cell cycle and proliferation after conventional treatments in Luminal A breast cancer patients.The candidate miRNAs (miRs), lncRNAs, and mRNAs were first taken from the Gene Expression Omnibus and TCGA databases. The lncRNA-miR-mRNA network was then constructed using the high-throughput sequencing data. The expression levels of selected targets were measured in the breast cancer and healthy samples by the Real-Time PCR technique and compared with the clinical outcomes by the Kaplan-Meier method.Our analysis revealed a group of differentially expressed 3 lncRNAs, 9 miRs, and 14 mRNAs in breast cancer patients. A significant expression decrease of the selected tumor suppressor lncRNAs, miRs, and genes and a substantial expression increase of the selected onco-lncRNAs, oncomiRs, and oncogenes were obtained in the patients compared to the healthy group. The plasma levels of the lncRNAs, miRs, and mRNAs were more significant after the operation, chemotherapy, and radiotherapy than the pre-treatment. The Kaplan-Meier analysis indicated that the patients with a high expression of miR-21, miR-20b, IGF1R, and E2F2 and a low expression of miR-125a, PDCD4, and PTEN had exhibited a shorter overall survival rate.Our results suggested that the underlying mechanisms of the lncRNA, miRs, and mRNAs and relevant signaling pathways may be considered predictive and therapeutic targets for breast cancer.

Entities:  

Keywords:  Breast tumor; chemotherapy; lncRNA; mRNA; microRNA; operation; radiotherapy

Mesh:

Substances:

Year:  2022        PMID: 35470783      PMCID: PMC9302505          DOI: 10.1080/15384101.2022.2070104

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  46 in total

Review 1.  Long non-coding RNA PVT1 and cancer.

Authors:  Ming Cui; Lei You; Xiaoxia Ren; Wenjing Zhao; Quan Liao; Yupei Zhao
Journal:  Biochem Biophys Res Commun       Date:  2016-02-03       Impact factor: 3.575

Review 2.  Polycomb silencers control cell fate, development and cancer.

Authors:  Anke Sparmann; Maarten van Lohuizen
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

Review 3.  Breast cancer.

Authors:  Nadia Harbeck; Frédérique Penault-Llorca; Javier Cortes; Michael Gnant; Nehmat Houssami; Philip Poortmans; Kathryn Ruddy; Janice Tsang; Fatima Cardoso
Journal:  Nat Rev Dis Primers       Date:  2019-09-23       Impact factor: 52.329

4.  LncRNADisease 2.0: an updated database of long non-coding RNA-associated diseases.

Authors:  Zhenyu Bao; Zhen Yang; Zhou Huang; Yiran Zhou; Qinghua Cui; Dong Dong
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

5.  Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study.

Authors:  Willemijne A M E Schrijver; Paul J van Diest; Cathy B Moelans
Journal:  Oncotarget       Date:  2017-01-10

6.  Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer.

Authors:  Gangga Anuraga; Wei-Jan Wang; Nam Nhut Phan; Nu Thuy An Ton; Hoang Dang Khoa Ta; Fidelia Berenice Prayugo; Do Thi Minh Xuan; Su-Chi Ku; Yung-Fu Wu; Vivin Andriani; Muhammad Athoillah; Kuen-Haur Lee; Chih-Yang Wang
Journal:  J Pers Med       Date:  2021-10-26

7.  A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.

Authors:  Solmaz Khalighfard; Mohammad Reza Kalhori; Taghi Amiriani; Amirhoushang Poorkhani; Vahid Khori; Ebrahim Esmati; Marzieh Lashkari; Ali Najafi; Ali Mohammad Alizadeh
Journal:  Cancer Biomark       Date:  2022       Impact factor: 4.388

8.  Comprehensive Analysis of lncRNA and miRNA Regulatory Network Reveals Potential Prognostic Non-coding RNA Involved in Breast Cancer Progression.

Authors:  Sheng Gao; Xun Lu; Jingjing Ma; Qian Zhou; RanRan Tang; Ziyi Fu; Fengliang Wang; Mingming Lv; Cheng Lu
Journal:  Front Genet       Date:  2021-06-18       Impact factor: 4.599

9.  Detection of urinary Chlamydia trachomatis, Mycoplasma genitalium and human papilloma virus in the first trimester of pregnancy by PCR method.

Authors:  Monireh Rahimkhani; A Mordadi; M Gilanpour
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-06-04       Impact factor: 3.944

10.  Comprehensive analysis of the aberrantly expressed lncRNA‑associated ceRNA network in breast cancer.

Authors:  Tayier Tuersong; Linlin Li; Zumureti Abulaiti; Shumei Feng
Journal:  Mol Med Rep       Date:  2019-04-15       Impact factor: 2.952

View more
  1 in total

1.  Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients.

Authors:  Sadaf Alipour; Solmaz Khalighfard; Vahid Khori; Taghi Amiriani; Mahboubeh Tajaldini; Mohammad Dehghan; Somayeh Sadani; Ramesh Omranipour; Gelareh Vahabzadeh; Bita Eslami; Ali Mohammad Alizadeh
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.